369 related articles for article (PubMed ID: 17295430)
1. New-onset psoriatic palmoplantaris pustulosis following infliximab therapy: a class effect?
Roux CH; Brocq O; Leccia N; Giacchero D; Breuil V; Albert C; Lacour J; Perrin C; Euller-Ziegler L
J Rheumatol; 2007 Feb; 34(2):434-7. PubMed ID: 17295430
[TBL] [Abstract][Full Text] [Related]
2. Psoriasis induced by tumor necrosis factor-alpha antagonist therapy: a case series.
Cohen JD; Bournerias I; Buffard V; Paufler A; Chevalier X; Bagot M; Claudepierre P
J Rheumatol; 2007 Feb; 34(2):380-5. PubMed ID: 17013997
[TBL] [Abstract][Full Text] [Related]
3. Development of new-onset psoriasis in a patient receiving infliximab for treatment of rheumatoid arthritis.
Chan CY; Browning JC; Larsen F; Hsu S
Dermatol Online J; 2008 Sep; 14(9):12. PubMed ID: 19061594
[TBL] [Abstract][Full Text] [Related]
4. Immune-mediated skin lesions in patients treated with anti-tumour necrosis factor alpha inhibitors.
Exarchou SA; Voulgari PV; Markatseli TE; Zioga A; Drosos AA
Scand J Rheumatol; 2009; 38(5):328-31. PubMed ID: 19579151
[TBL] [Abstract][Full Text] [Related]
5. Resolution of endothelial activation and down-regulation of Tie2 receptor in psoriatic skin after infliximab therapy.
Markham T; Mullan R; Golden-Mason L; Rogers S; Bresnihan B; Fitzgerald O; Fearon U; Veale DJ
J Am Acad Dermatol; 2006 Jun; 54(6):1003-12. PubMed ID: 16713454
[TBL] [Abstract][Full Text] [Related]
6. Anti-tumor necrosis factor therapy: 6 year experience of a single center in northern Israel and possible impact of health policy on results.
Braun-Moscovici Y; Markovits D; Rozin A; Toledano K; Nahir AM; Balbir-Gurman A
Isr Med Assoc J; 2008 Apr; 10(4):277-81. PubMed ID: 18548981
[TBL] [Abstract][Full Text] [Related]
7. Anti-tumor necrosis factor-alpha-induced psoriasis.
Sari I; Akar S; Birlik M; Sis B; Onen F; Akkoc N
J Rheumatol; 2006 Jul; 33(7):1411-4. PubMed ID: 16821276
[TBL] [Abstract][Full Text] [Related]
8. Psoriasis and pustular dermatitis triggered by TNF-{alpha} inhibitors in patients with rheumatologic conditions.
de Gannes GC; Ghoreishi M; Pope J; Russell A; Bell D; Adams S; Shojania K; Martinka M; Dutz JP
Arch Dermatol; 2007 Feb; 143(2):223-31. PubMed ID: 17310002
[TBL] [Abstract][Full Text] [Related]
9. The enigmatic development of psoriasis and psoriasiform lesions during anti-TNF therapy: a review.
Grinblat B; Scheinberg M
Semin Arthritis Rheum; 2008 Feb; 37(4):251-5. PubMed ID: 17640718
[TBL] [Abstract][Full Text] [Related]
10. Psoriasis induced by anti-tumor necrosis factor therapy: a class effect?
Richette P; Viguier M; Bachelez H; Bardin T
J Rheumatol; 2007 Feb; 34(2):438-9. PubMed ID: 17304662
[No Abstract] [Full Text] [Related]
11. The first decade of biologic TNF antagonists in clinical practice: lessons learned, unresolved issues and future directions.
Sfikakis PP
Curr Dir Autoimmun; 2010; 11():180-210. PubMed ID: 20173395
[TBL] [Abstract][Full Text] [Related]
12. Anti-TNF-alpha-induced systemic lupus syndrome.
Debandt M; Vittecoq O; Descamps V; Le Loët X; Meyer O
Clin Rheumatol; 2003 Feb; 22(1):56-61. PubMed ID: 12605321
[TBL] [Abstract][Full Text] [Related]
13. Biologic therapy (TNF-alpha antagonists)-induced psoriasis: a cytokine imbalance between TNF-alpha and IFN-alpha?
Cuchacovich R; Espinoza CG; Virk Z; Espinoza LR
J Clin Rheumatol; 2008 Dec; 14(6):353-6. PubMed ID: 19033869
[TBL] [Abstract][Full Text] [Related]
14. Focus on adverse events of tumour necrosis factor alpha blockade in juvenile idiopathic arthritis in an open monocentric long-term prospective study of 163 patients.
Gerloni V; Pontikaki I; Gattinara M; Fantini F
Ann Rheum Dis; 2008 Aug; 67(8):1145-52. PubMed ID: 17981916
[TBL] [Abstract][Full Text] [Related]
15. Leukocytoclastic vasculitis associated with tumor necrosis factor-alpha blocking agents.
Mohan N; Edwards ET; Cupps TR; Slifman N; Lee JH; Siegel JN; Braun MM
J Rheumatol; 2004 Oct; 31(10):1955-8. PubMed ID: 15468359
[TBL] [Abstract][Full Text] [Related]
16. Psoriasis and palmoplantar pustulosis associated with tumor necrosis factor-α inhibitors: the Mayo Clinic experience, 1998 to 2010.
Shmidt E; Wetter DA; Ferguson SB; Pittelkow MR
J Am Acad Dermatol; 2012 Nov; 67(5):e179-85. PubMed ID: 21752492
[TBL] [Abstract][Full Text] [Related]
17. Anti-tumour necrosis factor-alpha therapy increases body weight in patients with chronic plaque psoriasis: a retrospective cohort study.
Gisondi P; Cotena C; Tessari G; Girolomoni G
J Eur Acad Dermatol Venereol; 2008 Mar; 22(3):341-4. PubMed ID: 18005022
[TBL] [Abstract][Full Text] [Related]
18. Infliximab to etanercept switch in patients with spondyloarthropathies and psoriatic arthritis: preliminary data.
Delaunay C; Farrenq V; Marini-Portugal A; Cohen JD; Chevalier X; Claudepierre P
J Rheumatol; 2005 Nov; 32(11):2183-5. PubMed ID: 16265699
[TBL] [Abstract][Full Text] [Related]
19. Psoriasis and psoriatic arthritis induced in a patient treated with infliximab for Crohn's disease.
Tichy M; Tichy M; Kopova R; Sternbersky J; Ditrichova D
J Dermatolog Treat; 2012 Jun; 23(3):208-11. PubMed ID: 21254868
[TBL] [Abstract][Full Text] [Related]
20. Cutaneous side-effects in patients with rheumatic diseases during application of tumour necrosis factor-alpha antagonists.
Lee HH; Song IH; Friedrich M; Gauliard A; Detert J; Röwert J; Audring H; Kary S; Burmester GR; Sterry W; Worm M
Br J Dermatol; 2007 Mar; 156(3):486-91. PubMed ID: 17300238
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
